MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.healun.2025.12.030

Медицинская библиотека · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026

Preventing invasive aspergillosis in lung transplant recipients: A cost-utility analysis.

Bitterman Roni, Glembocki Aida, Walti Laura N, Husain Shahid, Pechlivanoglou Petros

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Invasive aspergillosis (IA) is a major cause of morbidity and mortality in lung transplant recipients. While most centers use universal prophylaxis, others opt for pre-emptive treatment. The optimal prevention strategy remains uncertain.

OBJECTIVE

To evaluate the cost-utility of universal antifungal prophylaxis versus pre-emptive therapy for preventing IA during the first post-transplant year, from an Ontario healthcare payer perspective.

METHODS

A state transition model with a lifetime horizon was developed. Transition probabilities, utilities, and costs were sourced from the literature as well as individual patient data. The base-case analysis assumed a relative risk of IA of 0.61 (95% CI: 0.33 to1.12) with universal prophylaxis compared to pre-emptive therapy. Outcomes included cumulative IA risk, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). Incremental net health benefit (INHB) was calculated using a cost-effectiveness threshold of C$50,000 per QALY. Costs and QALYs were discounted at 1.5%. Deterministic and probabilistic sensitivity analyses were conducted.

RESULTS

The lifetime IA risk was 15.6% with universal prophylaxis and 18.6% with pre-emptive therapy. Universal prophylaxis yielded more QALYs at higher cost, with an ICER of C$30,393 per QALY gained and an INHB of 0.03. Probabilistic sensitivity analysis showed universal prophylaxis was favored at cost-effectiveness thresholds above C$45,000, with considerable uncertainty in the C$35,000-C$45,000 range.

INTERPRETATION: Universal prophylaxis was the preferred strategy in the base-case scenario, with an ICER below the commonly accepted threshold of C$50,000 per QALY. However, results were sensitive to model inputs, emphasizing the need for robust clinical trials directly comparing these strategies.

Для цитирования: Bitterman Roni, Glembocki Aida, Walti Laura N, Husain Shahid, Pechlivanoglou Petros. Preventing invasive aspergillosis in lung transplant recipients: A cost-utility analysis.. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2026. DOI: 10.1016/j.healun.2025.12.030.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.